[1]俞伟峰,龚丽珍,王飞云.替格瑞洛治疗急性冠脉综合征的临床疗效及对炎性因子和心功能的影响[J].医学信息,2024,37(13):114-117.[doi:10.3969/j.issn.1006-1959.2024.13.023]
 Clinical Efficacy of Ticagrelor in the Treatment of Acute Coronary Syndrome and its Effect on Inflammatory Factors and Cardiac Function.Clinical Efficacy of Ticagrelor in the Treatment of Acute Coronary Syndrome and its Effect on Inflammatory Factors and Cardiac Function[J].Journal of Medical Information,2024,37(13):114-117.[doi:10.3969/j.issn.1006-1959.2024.13.023]
点击复制

替格瑞洛治疗急性冠脉综合征的临床疗效及对炎性因子和心功能的影响()
分享到:

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
37卷
期数:
2024年13期
页码:
114-117
栏目:
论著
出版日期:
2024-07-01

文章信息/Info

Title:
Clinical Efficacy of Ticagrelor in the Treatment of Acute Coronary Syndrome and its Effect on Inflammatory Factors and Cardiac Function
文章编号:
1006-1959(2024)13-0114-04
作者:
俞伟峰龚丽珍王飞云
(弋阳县人民医院急诊科1,心内科2,江西 弋阳 334400)
Author(s):
Clinical Efficacy of Ticagrelor in the Treatment of Acute Coronary Syndrome and its Effect on Inflammatory Factors and Cardiac Function
(Department of Emergency1,Department of Cardiology2,Yiyang County People’s Hospital,Yiyang 334400,Jiangxi,China)
关键词:
急性冠脉综合征替格瑞洛C反应蛋白心功能抗血小板治疗
Keywords:
Acute coronary syndromeTicagrelorC-reactive proteinCardiac functionAntiplatelet therapy
分类号:
R541.4
DOI:
10.3969/j.issn.1006-1959.2024.13.023
文献标志码:
A
摘要:
目的 研究替格瑞洛治疗急性冠脉综合征(ACS)的临床疗效及对患者炎症因子、心功能的影响。方法 选取2019年10月-2022年10月弋阳县人民医院收治的71例ACS患者,经随机数字表法分为对照组(35例)与观察组(36例)。对照组行常规药物治疗,观察组则在其基础上联合替格瑞洛治疗,比较两组临床疗效、炎性因子[C反应蛋白(CRP)、白介素(IL-6、IL-18)]、心功能[左室射血分数(LVEF)、左室舒张末期内径(LVEDD)]、主要不良心血管事件(MACE)及不良反应情况。结果 观察组治疗总有效率高于对照组(P<0.05)。两组治疗后CRP、IL-6、IL-18水平均低于治疗前,且观察组CRP、IL-6、IL-18水平低于对照组(P<0.05)。两组治疗后LVEF大于治疗前,LVEDD小于治疗前,且观察组LVEF大于对照组,LVEDD小于对照组(P<0.05)。观察组MACE发生率小于对照组(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论 替格瑞洛可提升ACS患者的临床疗效,下调炎症因子水平,改善心功能,可降低MACE风险,且不增加药物不良反应。
Abstract:
Objective To study the clinical efficacy of ticagrelor in the treatment of acute coronary syndrome (ACS) and its effect on inflammatory factors and cardiac function.Methods A total of 71 patients with ACS admitted to Yiyang County People’s Hospital from October 2019 to October 2022 were selected and divided into control group (35 patients) and observation group (36 patients) by random number table method. The control group was treated with conventional drugs, while the observation group was treated with ticagrelor on the basis of the control group. The clinical efficacy, inflammatory factors [C-reactive protein (CRP), interleukin (IL-6, IL-18)], cardiac function [left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter (LVEDD)], major adverse cardiovascular events (MACE) and adverse reactions were compared between the two groups.Results The total effective rate of the observation group was higher than that of the control group (P<0.05). After treatment, the levels of CRP, IL-6 and IL-18 in the two groups were lower than those before treatment, and the levels of CRP, IL-6 and IL-18 in the observation group were lower than those in the control group (P<0.05). After treatment, LVEF in the two groups was greater than that before treatment, LVEDD was less than that before treatment, and LVEF in the observation group was greater than that in the control group, LVEDD was less than that in the control group (P<0.05). The incidence of MACE in the observation group was lower than that in the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05).Conclusion Ticagrelor can improve the clinical efficacy of ACS patients, down-regulate the level of inflammatory factors, improve cardiac function, reduce the risk of MACE, and do not increase adverse drug reactions.

参考文献/References:

[1]秦巍,单伟超,薛文平,等.硫酸氢氯吡格雷与替格瑞洛治疗急性冠状动脉综合征患者的临床研究[J].中国临床药理学杂志,2023,39(10):1385-1388.[2]陈世祺,窦镜申,朱建国,等.低剂量与标准剂量替格瑞洛在中国急性冠脉综合征患者中有效性和安全性的系统评价[J].中国现代应用药学,2022,39(24):3290-3299.[3]王紫薇,徐绥宁,王嘉仪,等.替格瑞洛与氯吡格雷治疗高龄急性冠脉综合征患者有效性和安全性比较[J].心脏杂志,2022,34(4):389-393.[4]王潜,陈颖,左君丽,等.氯吡格雷和替格瑞洛对急性冠脉综合征支架术后患者血小板抑制效果、疗效及安全性比较[J].世界临床药物,2022,43(3):253-258.[5]陈水静,李建文,王倩,等.替格瑞洛延长双抗治疗对ACS患者PCI术后出血风险-临床获益影响[J].湖南师范大学学报(医学版),2021,18(2):41-44.[6]苏斌,刘迎午,刘搏江,等.老年女性急性冠状动脉综合征行介入治疗患者应用氯吡格雷和替格瑞洛一年的临床结局[J].中华老年心脑血管病杂志,2021,23(5):495-498.[7]张新超,于学忠,陈凤英,等.急性冠脉综合征急诊快速诊治指南(2019)[J].临床急诊杂志,2019,20(4):253-262.[8]李刚,王立静,龙会平,等.替格瑞洛对急性冠脉综合征患者外周血管内皮功能的影响研究[J].现代中西医结合杂志,2020,29(24):2677-2680.[9]孔令兴,李小华,欧阳洁淼.替格瑞洛联合氯吡格雷治疗急性冠状动脉综合征患者的临床研究[J].中国临床药理学杂志,2020,36(14):1942-1945.[10]汤宁成,杨巍,吴海义.瑞舒伐他汀联合替格瑞洛治疗急性冠脉综合征的疗效及对YKL-40 GMP-140的作用分析[J].河北医学,2019,25(12):2061-2064.[11]宋佳,吴玉波,刘利龙,等.替格瑞洛与氯吡格雷治疗急性冠脉综合征疗效和安全性比较的系统评价[J].中国医院用药评价与分析,2019,19(10):1236-1241.[12]Nevill AM.Marked differences in the pharmacokinetic and pharmacodynamic profiles of ticagrelor in patients undergoing treatment for ST elevation and non ST elevation myocardial [J].Heart (British Cardiac Society),2018,104(6):132-135.[13]毛建斌,刘政,安卿.替格瑞洛治疗急性冠脉综合征冠状动脉介入治疗术后的临床研究[J].中国病案,2019,20(4):94-98.[14]程秀俊,唐海沁.替格瑞洛在急性冠脉综合征患者治疗中的疗效和安全性评价[J].中国临床保健杂志,2019,22(2):237-241.[15]Fernando H,Duong T,Huynh K,et al.Lignocaine versus opioids in coronary intervention: assessing antiplatelet activity and ticagrelor levels (LOCAL) study[J].European Heart Journal,2021,42(1):724.[16]尹富禹,郭安红.替格瑞洛联合低分子肝素治疗急性冠脉综合征的疗效及对血清炎症因子和MACE的影响[J].心血管康复医学杂志,2018,27(5):581-585.[17]陈俊华,张存新,张淳.替格瑞洛对急性冠状动脉综合征患者外周血管内皮功能的保护作用[J].中华老年心脑血管病杂志,2018,20(10):1041-1044.[18]王大宇,赵善隽,梁嘉永,等.替格瑞洛对急性冠脉综合征患者血清高敏C反应蛋白及血浆同型半胱氨酸水平的影响[J].心血管康复医学杂志,2019,28(1):72-75.[19]郑舒,周冬翠,毕磊,等.替格瑞洛治疗老年急性冠脉综合征患者的效果及对炎性因子、心功能的影响[J].中国临床保健杂志,2018,21(4):446-449.[20]彭慧,陈苏,王四坤,等.重组人脑利钠肽联合替格瑞洛治疗急性冠脉综合征的疗效观察[J].中西医结合心脑血管病杂志,2018,16(2):216-220.[21]白玉豪,李树仁,郝潇,等.带量采购政策实施前后抗血小板药物治疗急性冠脉综合征的疗效及安全性对比分析[J].实用心脑肺血管病杂志,2022,30(3):28-32.[22]姜建邦.替格瑞洛对经皮冠脉介入治疗冠状动脉复杂病变的应用价值[D].济南:山东大学,2017.

相似文献/References:

[1]刘 华,康美尼,王兴华,等.替格瑞洛对oxLDL诱导的人脐静脉内皮细胞ICAM-1表达的影响[J].医学信息,2018,31(22):81.[doi:10.3969/j.issn.1006-1959.2018.22.022]
 LIU Hua,KANG Mei-ni,WANG Xing-hua,et al.Effect of Ticagrelor on the Expression of ICAM-1 in Human umbilical Vein Endothelial Cells Induced by oxLDL[J].Journal of Medical Information,2018,31(13):81.[doi:10.3969/j.issn.1006-1959.2018.22.022]
[2]赵殿儒,祁景蕊.不同剂量瑞舒伐他汀对急性冠脉综合征患者心功能和炎症因子的影响[J].医学信息,2019,32(01):148.[doi:10.3969/j.issn.1006-1959.2019.01.046]
 ZHAO Dian-ru,YAN Jing-rui.Effects of Different Doses of Rosuvastatin on Cardiac Function and Inflammatory Factors in Patients with Acute Coronary Syndrome[J].Journal of Medical Information,2019,32(13):148.[doi:10.3969/j.issn.1006-1959.2019.01.046]
[3]镡子鸣,叶怀阔,任长杰.超敏C反应蛋白及妊娠相关血浆蛋白A预测再发急性冠脉综合征的临床价值[J].医学信息,2019,32(08):173.[doi:10.3969/j.issn.1006-1959.2019.08.055]
 TAN Zi-ming,YE Huai-kuo,et al.Clinical Value of High-sensitivity C-reactive Protein and Pregnancy-associated Plasma Protein A in Predicting Recurrent Acute Coronary Syndrome[J].Journal of Medical Information,2019,32(13):173.[doi:10.3969/j.issn.1006-1959.2019.08.055]
[4]梁道博,姚卜飞,夏双燕.氯吡格雷联合阿司匹林治疗急性冠脉综合征疗效与 安全性的Meta分析[J].医学信息,2019,32(11):76.[doi:10.3969/j.issn.1006-1959.2019.11.021]
 LIANG Dao-bo,YAO Bu-fei,XIA Shuang-yan.Meta-analysis of the Efficacy and Safety of Clopidogrel Combined with Aspirin in the Treatment of Acute Coronary Syndrome[J].Journal of Medical Information,2019,32(13):76.[doi:10.3969/j.issn.1006-1959.2019.11.021]
[5]张 毅.替格瑞洛对不稳定型心绞痛患者PCI术后缺血事件及炎症因子水平的影响[J].医学信息,2022,35(13):130.[doi:10.3969/j.issn.1006-1959.2022.13.030]
 ZHANG Yi.Effect of Ticagrelor on Ischemic Events and Inflammatory Factors in Patients with Unstable Angina Pectoris After PCI[J].Journal of Medical Information,2022,35(13):130.[doi:10.3969/j.issn.1006-1959.2022.13.030]
[6]张牧秋,古俊楠,刘 瑜,等.NOACS治疗房颤合并急性冠脉综合征的研究[J].医学信息,2019,32(13):28.[doi:10.3969/j.issn.1006-1959.2019.13.010]
 ZHANG Mu-qiu,GU Jun-nan,LIU Yu,et al.Study of NOACS in the Treatment of Atrial Fibrillation Complicated with Acute Coronary Syndrome[J].Journal of Medical Information,2019,32(13):28.[doi:10.3969/j.issn.1006-1959.2019.13.010]
[7]王建强,刘 瑜,张牧秋,等.房颤伴ACS患者经皮冠状动脉介入术后抗栓研究[J].医学信息,2019,32(14):35.[doi:10.3969/j.issn.1006-1959.2019.14.013]
 WANG Jian-qiang,LIU Yu,ZHANG Mu-qiu,et al.Study on Antithrombotic after Percutaneous Coronary Intervention in Patients with Atrial Fibrillation and ACS[J].Journal of Medical Information,2019,32(13):35.[doi:10.3969/j.issn.1006-1959.2019.14.013]
[8]王 焕.替格瑞洛在氯吡格雷抵抗AMI患者PCI术后抗血小板治疗中的应用[J].医学信息,2019,32(24):153.[doi:10.3969/j.issn.1006-1959.2019.24.055]
 WANG Huan.Application of Ticagrelor in the Antiplatelet Therapy of Clopidogrel in Patients with AMI after PCI[J].Journal of Medical Information,2019,32(13):153.[doi:10.3969/j.issn.1006-1959.2019.24.055]
[9]孙 洋,高 山,宋 京,等.血尿酸、同型半胱氨酸、脑钠肽、肌钙蛋白Ⅰ与急性冠脉综合征病变程度的相关性[J].医学信息,2020,33(02):105.[doi:10.3969/j.issn.1006-1959.2020.02.028]
 SUN Yang,GAO Shan,SONG Jing,et al.Correlation Between Serum Uric Acid,Homocysteine,Brain Natriuretic Peptide,TroponinⅠ and the Severity of Acute Coronary Syndrome[J].Journal of Medical Information,2020,33(13):105.[doi:10.3969/j.issn.1006-1959.2020.02.028]
[10]史作霞,张文彦,李 馨,等.改良桡动脉止血器在老年ACS患者动脉穿刺后压迫止血中的效果[J].医学信息,2020,33(02):184.[doi:10.3969/j.issn.1006-1959.2020.02.060]
 SHI Zuo-xia,ZHANG Wen-yan,LI Xin,et al.Evaluation of Improved Radial Arterial Hemostatic Device in Compression Hemostasis After Arterial Puncture in Elderly Patients with ACS[J].Journal of Medical Information,2020,33(13):184.[doi:10.3969/j.issn.1006-1959.2020.02.060]

更新日期/Last Update: 1900-01-01